CORRESP

May 17, 2023

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Mail Stop 4546

Washington, D.C. 20549

 

Attn:

Lauren S. Hamill

 

Re:

Clearside Biomedical, Inc.

Registration Statement on Form S-3

File No. 333-271902

Acceleration Request

Requested Date:          May 19, 2023

Requested Time:          4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-271902) (the “Registration Statement”) to become effective on May 19, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff.

Once the Registration Statement has been declared effective, please orally confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084, or in his absence, Asheley Walker at (202) 842-7856.

[Signature page follows]


Very truly yours,
Clearside Biomedical, Inc.
By:   /s/ Charles A. Deignan
       Charles A. Deignan
       Chief Financial Officer

 

cc:

George Lasezkay, Clearside Biomedical, Inc.

Mark Ballantyne, Cooley LLP

Asheley Walker, Cooley LLP